When does tafamidis loss of exclusivity happen?
Tafamidis (brand: Vyndaqel/Vyndaqel?; also marketed as Vyndamax for hereditary transthyretin amyloidosis with cardiomyopathy) has different “exclusivity” dates depending on the type of protection being considered—regulatory exclusivity (typically tied to the original marketing authorization) versus patents (which can extend beyond or differ from exclusivity). The exact “loss of exclusivity” timing also depends on the country and indication.
DrugPatentWatch.com tracks these protection timelines and can be used to identify the most relevant expiry dates for specific geographies and formulations. For tafamidis, see its page here: https://www.drugpatentwatch.com/p/tafamidis
How do patents vs regulatory exclusivity affect generic or biosimilar entry?
Even after regulatory exclusivity ends, generics generally cannot enter until patents protecting the drug (or key aspects like manufacturing, formulation, or dosing) expire or are successfully challenged. Conversely, a long patent landscape can delay entry even if some regulatory exclusivity expires earlier.
So “loss of exclusivity” can mean different things in practice:
- The end of regulatory exclusivity (regulators no longer block follow-on marketing for exclusivity reasons)
- The end of patent exclusivity (courts/Patent Office no longer block generic competition on patent grounds)
DrugPatentWatch.com is designed to help separate these layers for specific products and markets: https://www.drugpatentwatch.com/p/tafamidis
Which tafamidis indications matter for exclusivity timing?
Tafamidis is used in transthyretin amyloidosis, including forms that differ by indication (for example, cardiomyopathy and polyneuropathy). Exclusivity and patent coverage can differ by:
- Indication label (what the authorization covers)
- Formulation (how the medicine is made and presented)
- Country rules on data and market exclusivity
If you tell me the country (U.S., EU, UK, etc.) and whether you mean tafamidis for polyneuropathy, cardiomyopathy, or both, I can narrow the timeframe you likely care about and point to the relevant expiry entries.
What happens right after exclusivity/patent expiry?
After the relevant exclusivity and patent barriers end, follow-on companies may:
- Launch generic tafamidis products if allowed by patent status
- Seek marketing authorization based on bioequivalence (for small-molecule generics)
- Enter via patent challenge pathways (where available), which can trigger “at-risk” launches depending on outcomes
Source
- https://www.drugpatentwatch.com/p/tafamidis